{"id":52283,"date":"2022-12-22T14:02:28","date_gmt":"2022-12-22T13:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/"},"modified":"2022-12-22T14:02:28","modified_gmt":"2022-12-22T13:02:28","slug":"dalrada-selects-new-independent-auditor-to-support-current-business-growth","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/","title":{"rendered":"Dalrada Selects New Independent Auditor to Support Current Business Growth"},"content":{"rendered":"
\n

SAN DIEGO–(BUSINESS WIRE)–Dalrada Corporation<\/a> (OTCQB: DFCO<\/a>, “Dalrada,” the \u201cCompany\u201d), a problem-solving innovator that takes on complex, multi-disciplinary challenges in health care, clean energy, precision manufacturing, and technology, announced today that it has named MGO (Macias Gini and O\u2019Connell LLP), as its new independent auditor beginning the quarter ending December 31, 2022.\n<\/p>\n

<\/a><\/p>\n

\n\u201cSelecting MGO represents a major step in Dalrada\u2019s transformation as a company,\u201d said Kyle McCollum, Chief Financial Officer of Dalrada. \u201cDBBMcKennon was a valuable partner for Dalrada as we underwent significant changes to our business prior to and during the COVID-19 pandemic. However, as our business continues to evolve, we need a firm with deep government expertise and a global presence to better align with our fastest-growing segments.\u201d\n<\/p>\n

\n\u201cCombined with our triple-digit growth in the 2022 fiscal year, using MGO\u2019s services is a major signal to the market,\u201d said Brian McGoff, President and Chief Operating Officer of Dalrada. \u201cThe need for this new selection is driven by a number of recent transformations we\u2019ve made. The first was the launch of Dalrada Energy Services (DES) in early 2022, bringing innovation and leadership to the ESG market. Strong market demand and multiple federal incentives suited to its offerings will pave the way for DES to experience significant growth in 2023.\u201d\n<\/p>\n

\nMr. McGoff continued, \u201cDalrada Precision Manufacturing complements these initiatives through significant investments in our heat pump and deposition technologies. In addition to strong, global demand, we also meet the requirements for legacy energy grants, the 2022 Chips and Science Act, and various manufacturing incentives within the Inflation Reduction Act, enabling us to create new and expanded manufacturing capabilities in the U.S. Through our discussions with MGO, we are confident they are the right firm to support and advise Dalrada on these initiatives as we continue on this path of significant growth.\u201d\n<\/p>\n

\nDalrada looks forward to forging a strong bond with the MGO auditing team to deliver efficient and accurate reporting on the Company\u2019s financial statements.\n<\/p>\n

\nFor additional information on Dalrada and its subsidiaries, please visit www.dalrada.com<\/a>.\n<\/p>\n

\nAbout Dalrada (DFCO)<\/b>\n<\/p>\n

\nDalrada Financial Corporation (OTCQB: DFCO<\/a>) is a forward-facing organization that continually produces disruptive products and services that accelerate positive change for current and future generations.\n<\/p>\n

\nSince 1982, Dalrada has redefined possibilities while boldly addressing global challenges with transformative innovations that drive targeted advances in emerging markets for a new era of human behavior and interaction, ensuring a bright future for the world around us.\n<\/p>\n

\nDalrada Financial Corporation is committed to positively impacting people, businesses, and the planet through sustainable solutions. For more information, please visit www.dalrada.com<\/a>, and follow us on Twitter<\/a>, Facebook<\/a>, and LinkedIn<\/a>.\n<\/p>\n

\nAbout MGO<\/b>\n<\/p>\n

\nAs one of the fastest-growing business advisory and CPA professional services firms in the country, MGO combines deep industry experience with well-established advisory and accounting solutions that deliver results. MGO clients range from global technology and life science leaders, public companies, and innovative startups from the largest government entities in the country, to the biggest names in sports and entertainment. MGO is ranked as one of the top CPA firms in the nation by Accounting Today and Inside Public Accounting.\n<\/p>\n

\nDisclaimer<\/b>\n<\/p>\n

\nStatements in this press release that are not historical facts, the statements are forward-looking, including statements regarding future revenues and sales projections, plans for future financing, the ability to meet operational milestones, marketing arrangements and plans, and shipments to and regulatory approvals in international markets. Such statements reflect management’s current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors and will be dependent upon a variety of factors including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our products and services in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the US Securities and Exchange Commission (“SEC”), including its annual report on Form 10-K.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia contact: Michael Eslinger meslinger@dalrada.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO–(BUSINESS WIRE)–Dalrada Corporation (OTCQB: DFCO, “Dalrada,” the \u201cCompany\u201d), a problem-solving innovator that takes on complex, multi-disciplinary challenges in health care, clean energy, precision manufacturing, and technology, announced today that it has named MGO (Macias Gini and O\u2019Connell LLP), as its new independent auditor beginning the quarter ending December 31, 2022. \u201cSelecting MGO represents a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52283","6":"format-standard","7":"category-industry"},"yoast_head":"\nDalrada Selects New Independent Auditor to Support Current Business Growth - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dalrada Selects New Independent Auditor to Support Current Business Growth - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO–(BUSINESS WIRE)–Dalrada Corporation (OTCQB: DFCO, “Dalrada,” the \u201cCompany\u201d), a problem-solving innovator that takes on complex, multi-disciplinary challenges in health care, clean energy, precision manufacturing, and technology, announced today that it has named MGO (Macias Gini and O\u2019Connell LLP), as its new independent auditor beginning the quarter ending December 31, 2022. \u201cSelecting MGO represents a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-22T13:02:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221222005124\/en\/1548317\/21\/Dalrada_-_Financial_LOGO-RGB_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Dalrada Selects New Independent Auditor to Support Current Business Growth\",\"datePublished\":\"2022-12-22T13:02:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/\"},\"wordCount\":747,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005124\\\/en\\\/1548317\\\/21\\\/Dalrada_-_Financial_LOGO-RGB_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/\",\"name\":\"Dalrada Selects New Independent Auditor to Support Current Business Growth - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005124\\\/en\\\/1548317\\\/21\\\/Dalrada_-_Financial_LOGO-RGB_Color.jpg\",\"datePublished\":\"2022-12-22T13:02:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005124\\\/en\\\/1548317\\\/21\\\/Dalrada_-_Financial_LOGO-RGB_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221222005124\\\/en\\\/1548317\\\/21\\\/Dalrada_-_Financial_LOGO-RGB_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dalrada Selects New Independent Auditor to Support Current Business Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dalrada Selects New Independent Auditor to Support Current Business Growth - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/","og_locale":"en_US","og_type":"article","og_title":"Dalrada Selects New Independent Auditor to Support Current Business Growth - Pharma Trend","og_description":"SAN DIEGO–(BUSINESS WIRE)–Dalrada Corporation (OTCQB: DFCO, “Dalrada,” the \u201cCompany\u201d), a problem-solving innovator that takes on complex, multi-disciplinary challenges in health care, clean energy, precision manufacturing, and technology, announced today that it has named MGO (Macias Gini and O\u2019Connell LLP), as its new independent auditor beginning the quarter ending December 31, 2022. \u201cSelecting MGO represents a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-22T13:02:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221222005124\/en\/1548317\/21\/Dalrada_-_Financial_LOGO-RGB_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Dalrada Selects New Independent Auditor to Support Current Business Growth","datePublished":"2022-12-22T13:02:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/"},"wordCount":747,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221222005124\/en\/1548317\/21\/Dalrada_-_Financial_LOGO-RGB_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/","url":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/","name":"Dalrada Selects New Independent Auditor to Support Current Business Growth - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221222005124\/en\/1548317\/21\/Dalrada_-_Financial_LOGO-RGB_Color.jpg","datePublished":"2022-12-22T13:02:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221222005124\/en\/1548317\/21\/Dalrada_-_Financial_LOGO-RGB_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221222005124\/en\/1548317\/21\/Dalrada_-_Financial_LOGO-RGB_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dalrada-selects-new-independent-auditor-to-support-current-business-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Dalrada Selects New Independent Auditor to Support Current Business Growth"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52283"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52283\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}